Form 4: Pfizer Executive Modifies Stock Appreciation Rights in Recent Transaction

Executive Vice President Rady A. Johnson modifies stock appreciation rights (SARs) and acquires phantom stock units in a recent transaction.

Summary

• Rady A. Johnson, an Executive Vice President at Pfizer Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the modification of existing stock appreciation rights (SARs), also referred to as total shareholder return units (TSRUs), and the acquisition of phantom stock units.
• Johnson modified 24,797 SARs with an exercise price of $42.3, extending their vesting and settlement dates from February 23, 2028, to February 23, 2030.
• He also modified 22,823 SARs with an exercise price of $45.96, extending their vesting and settlement dates from February 24, 2027, to February 24, 2029.
• These modifications were made under a one-time offer by Pfizer to extend the dates upon which the awards vest and settle by two years.
• Additionally, Johnson acquired 6 phantom stock units through the Pfizer Supplemental Savings Plan at a price of $29.27 per unit.
• These units are settled in cash upon separation from service and can be transferred to an alternative investment account at any time.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction. The modification of SARs could be viewed slightly positively as it indicates a long-term commitment from the executive.

Positives

• The modification of SARs could be seen as a positive sign, indicating Johnson's long-term commitment to Pfizer's success.
• The acquisition of phantom stock units through the savings plan demonstrates participation in company benefits.

Future Outlook

The document does not contain specific forward-looking statements, but the modification of SARs suggests a continued alignment of executive compensation with long-term shareholder value.

Industry Context

Executive compensation practices, including the use of stock appreciation rights and phantom stock units, are common in the pharmaceutical industry to incentivize performance and retain key personnel. The modification of SARs to extend vesting periods is a tool companies use to further align executive interests with long-term company performance.

Comparison to Industry Standards

• Pfizer's use of stock appreciation rights and phantom stock units aligns with industry practices at companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK).
• These companies also utilize equity-based compensation to incentivize executives and align their interests with shareholder value.
• The specific terms of these awards, such as vesting schedules and performance metrics, can vary significantly between companies.

Stakeholder Impact

• The modification of SARs could potentially impact shareholders by aligning executive compensation with long-term company performance.
• Employees may be indirectly affected by the executive's actions and their potential impact on the company's overall success.

Key Dates